SIGN UP
LOG IN
News
SLRX
0.4850
-5.00%
-0.0256
Weekly Report: what happened at SLRX last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at SLRX last week (0401-0405)?
Weekly Report · 04/08 11:22
Weekly Report: what happened at SLRX last week (0325-0329)?
Weekly Report · 04/01 11:20
12 Health Care Stocks Moving In Wednesday's Intraday Session
Stoke Therapeutics (NASDAQ:STOK) shares increased by 46.1% to $15.03 during Wednesday's regular session. The company's market cap stands at $671.1 million. Nutriband stock rose 24.33% as the company's Q4 earnings came out yesterday. Lixte Biotechnology and Ontrak also moved upwards.
Benzinga · 03/27 16:31
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Landos Biopharma, Inc. Shares jumped 171.2% to $21.70 on Monday. AbbVie and Landos signed a definitive agreement to acquire the company. Altamira Therapeutics Ltd. Shares climbed 70.1% after falling around 22% on Friday. GameStop Corp. Shares rose 8.4% after the company announced a separation.
Benzinga · 03/25 18:44
12 Health Care Stocks Moving In Monday's Pre-Market Session
Landos Biopharma (NASDAQ:LABP) shares moved upwards by 181.6% to $22.05 during Monday's pre-market session. Altamira Therapeutics shares rose 49.71% after their Q4 earnings report came out yesterday. Neuronetics stock increased by 18.19% in pre- market.
Benzinga · 03/25 13:05
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Salarius Pharmaceuticals, Inc. Shares rose sharply in pre-market trading following fourth-quarter results. The company posted a net loss of $0.9 million for the fourth quarter. Canopy Growth Corporation and Esperion Therapeutics were among the other stocks moving in the day's trading.
Benzinga · 03/25 12:03
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Cannabis legalization, drug approval, a delisting update and more are the biggest pre-market stock movers on Monday morning. Next e GO stock is rocketing more than 127% alongside heavy pre- market trading this morning. Salarius Pharmaceuticals shares are surging over 28% following cannabis legalization in Germany. The top 10 biggest losers include a company undergoing a reverse stock split.
Investorplace · 03/25 11:36
Weekly Report: what happened at SLRX last week (0318-0322)?
Weekly Report · 03/25 11:23
Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday
Wall Street expects Dada Nexus Limited to report quarterly earnings at 9 cents per share on revenue of $432.74 million after the closing bell on Monday. Salarius Pharmaceuticals, Inc. Is expected to release its fourth quarter results before the opening bell. Masimo Corporation shares rose sharply during Friday's after-hours trading session.
Benzinga · 03/25 06:50
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023
Salarius Pharmaceuticals reported earnings per share of -22 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. Salarius reported above the analyst estimate for EPS of -$1.01. The stock is down 1.7% today.
Investorplace · 03/23 01:52
12 Health Care Stocks Moving In Friday's After-Market Session
Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The company's market cap stands at $8.0 billion. Masimo shares rose 12.48% and NextCure shares declined by 9.5% during the same session.
Benzinga · 03/22 21:33
Salarius Pharmaceuticals GAAP EPS of -$3.84
Seeking Alpha · 03/22 20:17
Salarius Pharmaceuticals Q4 2023 GAAP EPS $(0.22) Beats $(1.01) Estimate
Benzinga · 03/22 20:07
*Salarius Pharmaceuticals Sees Funding Sufficient Into 1H25 >SLRX
Dow Jones · 03/22 20:06
BRIEF-Salarius Pharmaceuticals Q4 Net Income USD -900 Thousand
Reuters · 03/22 20:05
Press Release: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers. Company Implemented Significant Expense-reduction Measures to Extend Cash Runway.
Dow Jones · 03/22 20:05
Press Release: Salarius Pharmaceuticals Reports -2-
Salarius's ability to continue as a going concern is subject to risks and uncertainties. Salarius may not achieve the plans, carry out the intentions or meet the expectations of these forward-looking statements. The company's stock price has risen to $1.05. Salarian's stock is listed on the Nasdaq.
Dow Jones · 03/22 20:05
*Salarius Pharmaceuticals 4Q Loss/Shr 22c >SLRX
Dow Jones · 03/22 20:05
Weekly Report: what happened at SLRX last week (0311-0315)?
Weekly Report · 03/18 11:21
More
Webull provides a variety of real-time SLRX stock news. You can receive the latest news about Salarius Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLRX
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.